Browsing restrictions can be lifted for a fee.
ACRO Biomedical Co., Ltd. develops and produces biomaterial medical devices for human tissue engineering and regenerative medicine. The company was founded on June 26, 2014 and is headquartered in Kaoshiung, Taiwan.
6748
亞果生醫
-0.65%
(-0.01)
The most recent financial report for 亞果生醫 (6748) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6748's short-term business performance and financial health. For the latest updates on 6748's earnings releases, visit this page regularly.
According to the latest financial report, 亞果生醫 (6748) reported an Operating Profit of -45.23M with an Operating Margin of -339.67% this period, representing a decline of 53.56% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 亞果生醫 (6748) announced revenue of 13.32M, with a Year-Over-Year growth rate of -36.73%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 亞果生醫 (6748) held Total Cash and Cash Equivalents of 86.07M, accounting for 0.14 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 亞果生醫 (6748) did not achieve the “three margins increasing” benchmark, with a gross margin of 28%%, operating margin of -339.67%%, and net margin of -331.14%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6748's profit trajectory and future growth potential.
According to the past four quarterly reports, 亞果生醫 (6748)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.72. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
亞果生醫 (6748)'s Free Cash Flow (FCF) for the period is 1.81M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 60.63% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.